NT5E and lung cancer: Targeting the CD73/adenosine pathway or the involved receptors may thus provide a clear therapeutic gain in the treatment of lung cancer and other CD73/adenosine-rich thorax-associated neoplasms: we expect that inhibition of CD73/adenosine signaling will limit lung toxicity during thoracic irradiation without protecting the tumor or even reinstall anti-tumor immunity when applied during therapeutic irradiation of adenosine-rich tumors with high radioresistance such as NSCLC (138).